Home › Leukemia › North Carolina › Durham
Pag-aaral pangklinika para sa Leukemia sa Durham, NC
Isang pag-aaral para sa Leukemia ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Durham. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Nagre-recruitPhase 3
- Quetzal Site 27, Chapel Hill · 10 mi ang layo
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Nagre-recruitPhase 1/2
- Duke University Medical Center, Durham
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Nagre-recruitPhase 3
- Duke University Medical Center, Durham
- University of North Carolina, Chapel Hill, Chapel Hill · 10 mi ang layo
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
Nagre-recruit
- Lineberger Comphrehensive Cancer Center at University of North Carolina, Chapel Hill · 10 mi ang layo
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Nagre-recruitPhase 1/2
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill · 10 mi ang layo
Strength Training Exercise in Pediatric Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (STEP-ALL)
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi ang layo
Registry of Older Patients With Cancer
Nagre-recruitObservasyonal na pag-aaral
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi ang layo
A Study of Revumenib and Mezigdomide in People With Leukemia
Nagre-recruitPhase 1/2
- University of North Carolina (Data Collection Only), Chapel Hill · 10 mi ang layo
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Nagre-recruitPhase 2/3
- Duke University, Durham
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Nagre-recruitPhase 1
- Duke Blood Cancer Center, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Nagre-recruitObservasyonal na pag-aaral
- Massive Bio SYNERGY-AI site, Chapel Hill · 10 mi ang layo
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Nagre-recruitObservasyonal na pag-aaral
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi ang layo
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Nagre-recruitPhase 2
- Durham VA Medical Center, Durham, NC, Durham
Pag-aaral para sa Leukemia sa ibang lungsod
- Houston, TX28 pag-aaral
- Boston, MA25 pag-aaral
- New York City, NY19 pag-aaral
- Los Angeles, CA16 pag-aaral
- Chicago, IL16 pag-aaral
- Columbus, OH12 pag-aaral
- Baldwin Park, CA12 pag-aaral
- Nashville, TN12 pag-aaral
- Philadelphia, PA12 pag-aaral
- Seattle, WA11 pag-aaral
- Milwaukee, WI11 pag-aaral
- Birmingham, AL10 pag-aaral
Iba pang pag-aaral sa Durham
- Kanser sa Suso63 pag-aaral
- Kanser (lahat ng uri)59 pag-aaral
- Non-Small Cell Lung Cancer39 pag-aaral
- Multiple Myeloma37 pag-aaral
- Metastatic Cancer33 pag-aaral
- Acute Myeloid Leukemia33 pag-aaral
- Kanser sa Baga32 pag-aaral
- Kanser sa Prostate32 pag-aaral
- Colorectal Cancer28 pag-aaral
- Kanser sa Ovary27 pag-aaral
- Chronic Lymphocytic Leukemia27 pag-aaral
- Pagkabigo ng Puso26 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.